Welcome to our dedicated page for Burcon Nutrascience news (Ticker: BRCNF), a resource for investors and traders seeking the latest updates and insights on Burcon Nutrascience stock.
Burcon NutraScience Corporation reports developments tied to plant-based protein ingredients for the food and beverage industry. Company updates cover commercialization of high-performance protein products such as Peazzaz®, FavaPro and Puratein®, production scale-up, customer adoption across beverage, nutrition and plant-based food applications, and work with manufacturing partners to support demand.
Recurring news also includes operating and financial results, convertible-debenture financing, shareholder voting matters, warrant amendments, board changes and other governance actions. Burcon's communications frequently reference its patent portfolio for proteins derived from pea, canola, soy, hemp, sunflower and other plant sources.
Burcon NutraScience (TSX: BU) (OTCQB: BRCNF), a leader in plant-based protein technology, has announced a virtual Investor Presentation scheduled for February 18, 2025, at 5:00 p.m. Eastern time. The presentation will be led by CEO Kip Underwood to discuss recent company milestones.
The event will cover key topics including: the company's route to market through facility acquisition by alliance partner Re ProMan , plans to bring their entire protein portfolio to market with full operational control, details about their Rights Offering, and future plans. A live Q&A session will follow the presentation.
Investors can participate through a webcast available on Burcon's website under 'Presentations' or join via phone using toll-free number 1-800-717-1738 (North America) or 1-646-307-1865 (International) with Conference ID: 37581. Questions can be submitted in advance to plam@burcon.ca.
Burcon NutraScience (TSX: BU) (OTCQB: BRCNF) has entered into an agreement with RE ProMan, for a protein production facility in North America. The deal includes a seven-year manufacturing agreement followed by a ten-year lease arrangement. Under the terms, ProMan will purchase the facility and grant Burcon exclusive access to 100% of manufacturing capacity for its plant protein portfolio.
The agreement includes an annual production fee with a fixed portion totaling US$19.8 million over seven years, plus variable costs. First-year sales are projected at $1-3 million, with double-digit revenue expected in year two. Gross margins are targeted to exceed 50% as capacity utilization increases, with profitability and positive cash flow anticipated in 2026.
Due to ProMan being controlled by Burcon director John Vassallo, the agreement requires disinterested shareholder approval. The deal is conditional on Burcon receiving regulatory approvals, ProMan completing the facility acquisition by April 30, 2025, and Burcon securing minimum financing of CAD$7 million.
Burcon NutraScience (TSX: BU) (OTCQB: BRCNF) announced that its alliance partner, RE ProMan, , has signed a Purchase and Sale Agreement to acquire a protein production facility in North America. The agreement was signed by ProMan, led by John Vassallo, who is also a director and shareholder of Burcon.
The acquisition is subject to due diligence and approval by the parties. The facility was selected after reviewing several commercial locations capable of producing Burcon's entire protein portfolio. Burcon has prepared comprehensive plans for facility start-up, including raw material procurement, production ramp, and product launch.
Upon transaction closing, Burcon plans to install proprietary unit operations and begin commercial-scale production of its protein products during the first half of 2025. This acquisition will provide Burcon with direct market access for all its protein products and control over commercial production.
Burcon NutraScience (TSX: BU) (OTCQB: BRCNF) has launched Solatein™, a groundbreaking high-purity sunflower protein isolate. The product features over 90% protein purity and is designed to meet growing consumer demand for protein supplements, particularly among GLP-1 weight management medication users.
Solatein™ offers unique characteristics including neutral flavor, off-white color, and exceptional functionality for food and beverage applications. The non-GMO, hypoallergenic protein is rich in sulfur-containing amino acids and is produced through an innovative process that upcycles sunflower seed oil production by-products.
According to Goldman Sachs Research, GLP-1 medication users are expected to increase significantly over the next five years, creating new opportunities in the protein supplement market. Burcon's expanded portfolio aims to address this growing demand with its highly differentiated plant-based protein solutions.
Burcon NutraScience (TSX: BU) (OTCQB: BRCNF) has provided an update on its previously announced rights offering. The company has secured registration requirement exemptions in Arizona, Arkansas, Minnesota, and Wisconsin, allowing shareholders in these states to participate in the offering.
Each shareholder of record as of November 27, 2024, will receive one transferable right for each common share held, enabling them to purchase one common share at $0.085. The rights are trading on TSX under 'BU.RT' until February 12, 2025. Shareholders must complete a subscription form and submit payment by 5:00 p.m. Eastern time on that date.
Ineligible shareholders outside eligible jurisdictions must complete an Exempt Purchaser Status Certificate by February 5, 2025, to participate.
Burcon NutraScience (TSX: BU) (OTCQB: BRCNF) has been granted three new patents by the United States Patent and Trademark Office (USPTO). Two patents cover the production process and consumer applications for Peazazz pea protein, while one patent is for the production process of their soy protein.
The specific patents granted are U.S. patents 12,102,100 and 12,108,774 for pea protein, and U.S. patent 12,089,614 for soy protein. These additions expand Burcon's intellectual property portfolio to over 100 issued patents globally, including 61 U.S. patents, with more than 80 pending patent applications (12 in the U.S.).
Burcon NutraScience has launched its next-generation Peazazz®C pea protein, featuring over 90% protein purity and low sodium content. The product, made from North American non-GMO field peas, is designed for various applications including beverages, dairy alternatives, baked goods, and nutrition products. The company has accelerated its launch timeline to expedite customer evaluation processes, with several prospective customers already familiar with Burcon's pea protein technology. The proprietary technology transforms yellow field peas into high-purity protein isolates with neutral flavor and light color.
Burcon NutraScience (TSX: BU) (OTCQB: BRCNF) has announced a partnership with Puratos, a global provider of bakery, patisserie, and chocolate ingredients with over US$3.1 billion in net sales. The collaboration aims to develop innovative applications for Burcon's Puratein® canola protein in the bakery and patisserie sectors. The partnership focuses on creating sustainable and healthier alternatives to egg protein, leveraging canola protein's neutral flavor, functional versatility, and high nutritional value. Together, they will work on developing canola protein-enhanced solutions through Puratos's global R&D network to meet growing consumer demand for nutritious and environmentally friendly options.
Burcon NutraScience announces a Rights Offering to existing shareholders, allowing them to purchase one common share at $0.085 for each share held as of November 27, 2024. This represents a 39% discount to the 5-day volume weighted average trading price. The offering could raise approximately $11.9 million in net proceeds through issuing up to 142,628,096 common shares. The Rights will trade on TSX under 'BU.RT' until February 12, 2025. Insider Group, holding 28.44% of shares, intends to exercise their rights. Proceeds will fund operational costs and explore production capacity expansion opportunities through potential facility leasing.
Burcon NutraScience has formed an alliance with a strategic investor group to acquire and operate a commercial protein production facility. The investor group, led by a Burcon board member, will fund the acquisition while Burcon will operate the facility. The acquisition is expected to close in Q1 2025, with production starting in H1 2025.
This strategic move will enable Burcon to launch its entire portfolio of plant-based protein ingredients. The company has built a pipeline of over 80 prospective customers evaluating its protein ingredients, with several in late-stage product trials for hemp and canola proteins. The facility acquisition aims to accelerate new protein launches and increase market share in the protein ingredient market.